Quick Answer
Immunovant, Inc. reported Net Income of -$413.84 million for fiscal year 2025.
Immunovant, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$413.84M | -59.6% |
| 2024 | -$259.34M | -22.9% |
| 2023 | -$210.96M | -34.6% |
| 2022 | -$156.73M | -45.9% |
| 2021 | -$107.43M | -61.8% |
| 2020 | -$66.39M | -132.1% |
| 2019 | -$28.60M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | -$110.64M | +0.4% | +12.5% |
| September 30, 2025 | -$126.50M | -15.9% | -4.9% |
| June 30, 2025 | -$120.61M | -38.4% | -8.5% |
| December 31, 2024 | -$111.12M | -116.1% | -1.8% |
| September 30, 2024 | -$109.12M | -86.0% | -25.2% |
| June 30, 2024 | -$87.15M | -17.9% | -69.5% |
| December 31, 2023 | -$51.42M | +18.7% | +12.3% |
| September 30, 2023 | -$58.66M | -22.4% | +20.7% |
- Immunovant, Inc. showed a decrease of -59.6% in Net Income compared to the prior fiscal year.
- Over the 2019–2025 period, Immunovant, Inc.’s net income has declined by 1347.0% (from -$28.60 million to -$413.84 million).
- The most recent figure is from Immunovant, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on May 29, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: